Hologic enters into amended and restated five-year secured credit agreement

Hologic enters into amended and restated five-year secured credit agreement
share Share

- Initial Proceeds from New $1.5 Billion Term Loan and $1.5 Billion Revolving Credit Line Used to Refinance Senior Secured Debt -
- Funds Also Expected to Contribute to Retirement of Remaining Convertible Notes -


Hologic, Inc. (NASDAQ: HOLX) has announced  that the Company has entered into an amended and restated credit agreement consisting of a new, five-year $1.5 billion senior term loan and $1.5 billion revolving credit facility.


Hologic has used the initial proceeds from the credit agreement to pay off the Company's previous senior secured term loan and revolver. 


"This new credit agreement extends our debt maturities and increases our financial flexibility," said Bob McMahon, Hologic's Chief Financial Officer.  "In addition, increasing the size of our revolver will provide some of the capacity to retire our remaining convertible notes when they become callable."


The new loan facilities mature on October 3, 2022, subject to adjustment in certain circumstances.  Borrowings initially bear interest at an annual rate of LIBOR + 1.50%, and may change based on Hologic's leverage ratio.  Prior to maturity, the Company will be required to make minimum principal payments on the new term loan in annualized amounts of $37.5 million in fiscal 2018, $75 million in fiscal 2019, $75 million in fiscal 2020, $112.5 million in fiscal 2021, and $150 million in fiscal 2022, with the balance due at maturity.


Hologic has initially borrowed $345 million against the new revolving credit facility.  The revolver initially carries an unused fee of 0.25% annually, which may change based on the Company's leverage ratio.  In connection with the refinancing, Hologic terminated its previous $1 billion revolving credit facility.

Multiple bank lenders participated in the financing, which was led by Bank of America Merrill Lynch.


Source & Image Credit: Hologic


Find More About Hologic

Published on : Wed, 4 Oct 2017



Related Articles
Panther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System

- New Panther Fusion Module Expands System's Molecular Testing Capabilities, Increases Efficiency and Flexibility for the Laboratory   Hologic, Inc.... Read more

Hologic Receives CE Mark to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)

Patients in Clinical Studies Report 100% Satisfaction Hologic, Inc. (Nasdaq: HOLX) has announced that it has received an additional... Read more

Paraflu Assay Now FDA Cleared on Hologic's New Panther Fusion® System

-- New Assay Extends Respiratory Testing Menu; Modular Panels and Fusion System Increase Efficiency and Flexibility for the Laboratory... Read more

Hologic,credit agreement,credit facility,Bob McMahon, ,Chief Financial Officer,Bank of America Merrill Lynch Hologic, Inc. (NASDAQ: HOLX) has announced that the Company has entered into an amended and restated credit agreement consisting of a new, five-year $1.5 billion senior term loan and $1.5 billion revolving credit facility.

No comment


Please login to leave a comment...

Highlighted Products